Tandem Mass Tag-Based Proteomic Analysis of Potential Biomarkers for Hepatocellular Carcinoma Differentiation

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Fujiyama S, Tanaka M, Maeda S, Ashihara H, Hirata R, Tomita K. Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology. 2002;62(suppl1):57–63. doi:10.1159/000048277
   PubMedGoogle Scholar
• Gupta S, Bent S, Kohlwes J. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med. 2003;139(1):46–50. doi:10.7326/0003-4819-139-1-200307010-00012
   PubMed Web of Science ®Google Scholar
• Zhang D, Lim SG, Koay ES. Proteomic identification of down-regulation of oncoprotein DJ-1 and proteasome activator subunit 1 in hepatitis B virus-infected well-differentiated hepatocellular carcinoma. Int J Oncol. 2007;31(3):577–584.
   PubMed Web of Science ®Google Scholar
• Ker CG, Chen HY, Chen KS, et al. Clinical significance of cell differentiation in hepatocellular carcinoma. Hepato-Gastroenterology. 2003;50(50):475–479.
   PubMedGoogle Scholar
• Takashima M, Kuramitsu Y, Yokoyama Y, et al. Overexpression of alpha enolase in hepatitis C virus-related hepatocellular carcinoma: association with tumor progression as determined by proteomic analysis. Proteomics. 2005;5(6):1686–1692. doi:10.1002/pmic.200401022
   PubMed Web of Science ®Google Scholar
• Ding SJ, Li Y, Tan YX, et al. From proteomic analysis to clinical significance: overexpression of cytokeratin 19 correlates with hepatocellular carcinoma metastasis. Molecular Cellular proteomics. 2004;3(1):73–81. doi:10.1074/mcp.M300094-MCP200
   PubMed Web of Science ®Google Scholar
• Kuramitsu Y, Harada T, Takashima M, et al. Increased expression and phosphorylation of liver glutamine synthetase in well-differentiated hepatocellular carcinoma tissues from patients infected with hepatitis C virus. Electrophoresis. 2006;27(8):1651–1658. doi:10.1002/elps.200500718
   PubMed Web of Science ®Google Scholar
• Nissom PM, Lo SL, Lo JCY, et al. Hcc-2, a novel mammalian ER thioredoxin that is differentially expressed in hepatocellular carcinoma. FEBS Lett. 2006;580(9):2216–2226. doi:10.1016/j.febslet.2006.03.029
   PubMed Web of Science ®Google Scholar
• Cao Y, Ding W, Zhang J. Significant down-regulation of urea cycle generates clinically relevant proteomic signature in hepatocellular carcinoma patients with macrovascular invasion. J Proteome Res. 2019;18(5):2032–2044.
   Google Scholar
• Li C, Tan Y-X, Zhou H, et al. Proteomic analysis of hepatitis B virus-associated hepatocellular carcinoma: identification of potential tumor markers. Proteomics. 2005;5(4):1125–1139. doi:10.1002/pmic.200401141
   PubMed Web of Science ®Google Scholar
• Iizuka N, Oka M, Yamada-Okabe H, et al. Comparison of gene expression profiles between Hepatitis B Virus- and Hepatitis C Virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method. Cancer Res. 2002;62(14):3939.
   PubMed Web of Science ®Google Scholar
• Wei D, Zeng Y, Xing X, et al. Proteome differences between hepatitis B Virus Genotype-B- and Genotype-C-Induced hepatocellular carcinoma revealed by iTRAQ-Based quantitative proteomics. J Proteome Res. 2016;15(2):487–498. doi:10.1021/acs.jproteome.5b00838
   PubMed Web of Science ®Google Scholar
• Li C, Hong Y, Tan Y-X, et al. Accurate qualitative and quantitative proteomic analysis of clinical hepatocellular carcinoma using laser capture microdissection coupled with isotope-coded affinity tag and two-dimensional liquid chromatography mass spectrometry. Molecular Cellular Proteomics. 2004;3(4):399. doi:10.1074/mcp.M300133-MCP200
   PubMed Web of Science ®Google Scholar
• Liang CRMY, Leow CK, Neo JCH, et al. Proteome analysis of human hepatocellular carcinoma tissues by two-dimensional difference gel electrophoresis and mass spectrometry. Proteomics. 2005;5(8):2258–2271. doi:10.1002/pmic.200401256
   PubMed Web of Science ®Google Scholar
• Kim W, Oe Lim S, Kim J-S, et al. Comparison of proteome between Hepatitis B Virus- and Hepatitis C virus-associated hepatocellular carcinoma. Clin Cancer Res. 2003;9(15):5493.
   PubMed Web of Science ®Google Scholar
• Arntzen MØ, Koehler CJ, Barsnes H, Berven FS, Treumann A. IsobariQ: software for Isobaric Quantitative Proteomics using IPTL, iTRAQ, and TMT. J Proteome Res. 2011;10(2):913–920. doi:10.1021/pr1009977
   PubMed Web of Science ®Google Scholar
• Zhou J, Sun HC, Wang Z, et al. Guidelines for diagnosis and treatment of primary liver cancer in China (2017 Edition). Liver Cancer. 2018;7(3):235–260. doi:10.1159/000488035
   PubMed Web of Science ®Google Scholar
• Okawa T, Michaylira CZ, Kalabis J, et al. The functional interplay between EGFR overexpression, hTERT activation, and p53 mutation in esophageal epithelial cells with activation of stromal fibroblasts induces tumor development, invasion, and differentiation. Genes Dev. 2007;21(21):2788–2803. doi:10.1101/gad.1544507
   PubMed Web of Science ®Google Scholar
• Holmes FL. Hans Krebs and the discovery of the ornithine cycle. Fed Proc. 1980;39(2):216–225.
   PubMedGoogle Scholar
• Krebs HA. The history of the tricarboxylic acid cycle. Perspectives Biol Med Autumn. 1970;14(1):154–170. doi:10.1353/pbm.1970.0001
   PubMed Web of Science ®Google Scholar
• Pegg AE. Mammalian polyamine metabolism and function. IUBMB Life. 2009;61(9):880–894. doi:10.1002/iub.230
   PubMed Web of Science ®Google Scholar
• Delage B, Fennell DA, Nicholson L, et al. Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int J Cancer. 2010;126(12):2762–2772. doi:10.1002/ijc.25202
   PubMed Web of Science ®Google Scholar
• Wu L, Li L, Meng S, Qi R, Mao Z, Lin M. Expression of argininosuccinate synthetase in patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2013;28(2):365–368. doi:10.1111/jgh.12043
   PubMed Web of Science ®Google Scholar
• Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA. Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and <strong>in Vivo</strong&gt. Cancer Res. 2002;62(19):5443.
   PubMed Web of Science ®Google Scholar
• Tan GS, Lim KH, Tan HT, et al. Novel proteomic biomarker panel for prediction of aggressive metastatic hepatocellular carcinoma relapse in surgically resectable patients. J Proteome Res. 2014;13(11):4833–4846. doi:10.1021/pr500229n
   PubMed Web of Science ®Google Scholar
• Maglott D, Ostell J, Pruitt KD, Tatusova T. Entrez Gene: gene-centered information at NCBI. Nucleic Acids Res. 2011;39(Databaseissue):D52–57. doi:10.1093/nar/gkq1237
   PubMedGoogle Scholar
• Siddiqui MT, Hossein Saboorian M, Tunc Gokaslan S, Ashfaq R. Diagnostic utility of the HepPar1 antibody to differentiate hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration samples. Cancer Cytopathol. 2002;96(1):49–52. doi:10.1002/cncr.10311
   Web of Science ®Google Scholar
• Butler SL, Dong H, Cardona D, et al. The antigen for Hep Par 1 antibody is the urea cycle enzyme carbamoyl phosphate synthetase 1. Laboratory Investigation. 2008;88(1):78–88. doi:10.1038/labinvest.3700699
   PubMed Web of Science ®Google Scholar
• Liu H, Dong H, Robertson K, Liu C. DNA methylation suppresses expression of the urea cycle enzyme carbamoyl phosphate synthetase 1 (CPS1) in human hepatocellular carcinoma. Am J Pathol. 2011;178(2):652–661. doi:10.1016/j.ajpath.2010.10.023
   PubMed Web of Science ®Google Scholar
• Yang C, Fu R, Zhuang Z, Wang S. Studies on the biological functions of CPS1 in AFB1 induced hepatocarcinogenesis. Gene. 2016;591(1):255–261. doi:10.1016/j.gene.2016.07.031
   PubMed Web of Science ®Google Scholar
• Shahid M, Mubeen A, Tse J, et al. Branched chain in situ hybridization for albumin as a marker of hepatocellular differentiation: evaluation of manual and automated in situ hybridization platforms. Am J Surg Pathol. 2015;39(1):25–34. doi:10.1097/PAS.0000000000000343
   PubMed Web of Science ®Google Scholar
• Cheng H, Wang L, Mollica M, Re AT, Wu S, Zuo L. Nitric oxide in cancer metastasis. Cancer Lett. 2014;353(1):1–7. doi:10.1016/j.canlet.2014.07.014
   PubMed Web of Science ®Google Scholar
• Kaluarachchi DC, Smith CJ, Klein JM, Murray JC, Dagle JM, Ryckman KK. Polymorphisms in urea cycle enzyme genes are associated with persistent pulmonary hypertension of the newborn. Pediatr Res. 2018;83(1):142–147. doi:10.1038/pr.2017.143
   PubMed Web of Science ®Google Scholar
• Solis JA, Betancor P, Campos R, et al. Association of porphyria cutanea tarda and primary liver cancer: report of ten cases. J Dermatol. 1982;9(2):131–137. doi:10.1111/j.1346-8138.1982.tb02614.x
   PubMedGoogle Scholar
• Salata H, Cortés JM, de Salamanca RE, et al. Porphyria cutanea tarda and hepatocellular carcinoma: frequency of occurrence and related factors. J Hepatol. 1985;1(5):477–487. doi:10.1016/S0168-8278(85)80746-7
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Garcı́a-Buey L, Marı́a Pajares J, Moreno-Otero R. Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis. J Hepatol. 2003;39(4):620–627. doi:10.1016/S0168-8278(03)00346-5
   PubMed Web of Science ®Google Scholar
• Khan R, Zahid S, Wan YJ, et al. Protein expression profiling of nuclear membrane protein reveals potential biomarker of human hepatocellular carcinoma. Clin Proteomics. 2013;10(1):6. doi:10.1186/1559-0275-10-6
   PubMedGoogle Scholar
• Moukhadder HM, Halawi R, Cappellini MD, Taher AT. Hepatocellular carcinoma as an emerging morbidity in the thalassemia syndromes: a comprehensive review. Cancer. 2017;123(5):751–758. doi:10.1002/cncr.30462
   PubMed Web of Science ®Google Scholar
• Giardina B, Messana I, Scatena R, Castagnola M. The multiple functions of hemoglobin. Crit Rev Biochem Mol Biol. 1995;30(3):165–196. doi:10.3109/10409239509085142
   PubMed Web of Science ®Google Scholar
• Yang Q, Bai SY, Li LF, et al. Human hemoglobin subunit beta functions as a pleiotropic regulator of RIG-I/MDA5-Mediated antiviral innate immune responses. J Virol. 2019;93:16. doi:10.1128/JVI.00718-19
   Web of Science ®Google Scholar
• Lee NP, Chen L, Lin MC, et al. Proteomic expression signature distinguishes cancerous and nonmalignant tissues in hepatocellular carcinoma. J Proteome Res. 2009;8(3):1293–1303. doi:10.1021/pr800637z
   PubMed Web of Science ®Google Scholar
• Rozpedek W, Pytel D, Mucha B, Leszczynska H, Diehl JA, Majsterek I. The Role of the PERK/eIF2alpha/ATF4/CHOP signaling pathway in tumor progression during endoplasmic reticulum stress. Curr Mol Med. 2016;16(6):533–544. doi:10.2174/1566524016666160523143937
   PubMed Web of Science ®Google Scholar
• Moon HW, Han HG, Jeon YJ. Protein quality control in the endoplasmic reticulum and cancer. Int J Mol Sci. 2018;19:10. doi:10.3390/ijms19103020
   Web of Science ®Google Scholar
• Gao Y, Liu HY, Ni XZ. Elementary the transformation of cancer cell. J Changchun Teachers College. 2002.
   Google Scholar
• Rulten SL, Kinloch RA, Tateossian H, Robinson C, Gettins L, Kay JE. The human FK506-binding proteins: characterization of human FKBP19. Mammalian Genome. 2006;17(4):322–331.
   PubMed Web of Science ®Google Scholar
• Lin IY, Yen CH, Liao YJ, et al. Identification of FKBP11 as a biomarker for hepatocellular carcinoma. Anticancer Res. 2013;33(6):2763–2769.
   PubMed Web of Science ®Google Scholar
• Shuda M, Kondoh N, Imazeki N, et al. Activation of the ATF6, XBP1 and grp78 genes in human hepatocellular carcinoma: a possible involvement of the ER stress pathway in hepatocarcinogenesis. J Hepatol. 2003;38(5):605–614. doi:10.1016/S0168-8278(03)00029-1
   PubMed Web of Science ®Google Scholar
• Li D, Liu X, Zhou J, et al. Long noncoding RNA HULC modulates the phosphorylation of YB-1 through serving as a scaffold of extracellular signal–regulated kinase and YB-1 to enhance hepatocarcinogenesis. Hepatology. 2017;65(5):1612–1627. doi:10.1002/hep.29010
   PubMed Web of Science ®Google Scholar
• Pagano C, Di Martino O, Ruggiero G, et al. The tumor-associated YB-1 protein: new player in the circadian control of cell proliferation. Oncotarget. 2017;8(4):6193–6205. doi:10.18632/oncotarget.14051
   PubMedGoogle Scholar
• Shiota M, Fujimoto N, Imada K, et al. Potential Role for YB-1 in castration-resistant prostate cancer and resistance to enzalutamide through the androgen receptor V7. J Natl Cancer Inst. 2016;108(7):Jul. doi:10.1093/jnci/djw005
   Google Scholar
• Chao HM, Huang HX, Chang PH, Tseng KC, Miyajima A, Chern E. Y-box binding protein-1 promotes hepatocellular carcinoma-initiating cell progression and tumorigenesis via Wnt/beta-catenin pathway. Oncotarget. 2017;8(2):2604–2616. doi:10.18632/oncotarget.13733
   PubMedGoogle Scholar
• Chen YR, Sekine K, Nakamura K, Yanai H, Tanaka M, Miyajima A. Y-box binding protein-1 down-regulates expression of carbamoyl phosphate synthetase-I by suppressing CCAAT enhancer-binding protein-alpha function in mice. Gastroenterology. 2009;137(1):330–340. doi:10.1053/j.gastro.2009.02.064
   PubMed Web of Science ®Google Scholar